CO6630187A2 - 5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak - Google Patents

5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak

Info

Publication number
CO6630187A2
CO6630187A2 CO12203751A CO12203751A CO6630187A2 CO 6630187 A2 CO6630187 A2 CO 6630187A2 CO 12203751 A CO12203751 A CO 12203751A CO 12203751 A CO12203751 A CO 12203751A CO 6630187 A2 CO6630187 A2 CO 6630187A2
Authority
CO
Colombia
Prior art keywords
pyrimidines
imidazol
substituted
kinase inhibitors
jak kinase
Prior art date
Application number
CO12203751A
Other languages
English (en)
Spanish (es)
Inventor
Mark L Boys
Laurence E Burgess
Robert Groneberg
Darren Harvey
Lily Huang
Timothy Kercher
Chrsitopher F Kraser
Ellen Laird
Eugene Tarlton
Qian Zhao
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CO6630187A2 publication Critical patent/CO6630187A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO12203751A 2010-04-14 2012-11-13 5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak CO6630187A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32418610P 2010-04-14 2010-04-14

Publications (1)

Publication Number Publication Date
CO6630187A2 true CO6630187A2 (es) 2013-03-01

Family

ID=43984073

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12203751A CO6630187A2 (es) 2010-04-14 2012-11-13 5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak

Country Status (21)

Country Link
US (1) US8962596B2 (enExample)
EP (1) EP2558468B1 (enExample)
JP (2) JP2013523884A (enExample)
KR (1) KR20130094710A (enExample)
CN (1) CN102985424B (enExample)
AR (1) AR081075A1 (enExample)
AU (1) AU2011240808B2 (enExample)
CA (1) CA2796388A1 (enExample)
CL (1) CL2012002882A1 (enExample)
CO (1) CO6630187A2 (enExample)
CR (1) CR20120572A (enExample)
MX (1) MX2012011941A (enExample)
NZ (1) NZ603446A (enExample)
PH (1) PH12012502046A1 (enExample)
RU (1) RU2012148246A (enExample)
SG (1) SG184870A1 (enExample)
TW (1) TWI494314B (enExample)
UA (1) UA109131C2 (enExample)
UY (1) UY33328A (enExample)
WO (1) WO2011130146A1 (enExample)
ZA (1) ZA201208544B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2455382T1 (sl) 2005-12-13 2017-03-31 Incyte Holdings Corporation S heteroarilom substituirani pirolo(2,3b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janus kinaze
ES2467665T5 (es) 2007-06-13 2022-11-03 Incyte Holdings Corp Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PT2432472T (pt) 2009-05-22 2019-12-09 Incyte Holdings Corp 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- ou heptano-nitrilo como inibidores de jak
KR101903354B1 (ko) 2009-06-17 2018-10-04 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX354212B (es) 2010-03-10 2018-02-19 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
US20110288107A1 (en) 2010-05-21 2011-11-24 Bhavnish Parikh Topical formulation for a jak inhibitor
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
KR20140014110A (ko) 2010-12-16 2014-02-05 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
WO2012177606A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) * 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
SG11201401342VA (en) * 2011-10-12 2014-09-26 Array Biopharma Inc 5,7-substituted-imidazo[1,2-c]pyrimidines
AU2012336019A1 (en) * 2011-11-07 2014-05-29 Vertex Pharmaceuticals Incorporated Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2014065791A1 (en) 2012-10-24 2014-05-01 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
ES2880814T3 (es) 2012-11-15 2021-11-25 Incyte Holdings Corp Formas de dosificación de liberación sostenida de ruxolitinib
US20160123982A1 (en) 2013-02-04 2016-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
WO2014146249A1 (en) 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
EA201591881A1 (ru) * 2013-03-28 2016-04-29 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение
WO2014172639A1 (en) * 2013-04-19 2014-10-23 Ruga Corporation Raf kinase inhibitors
PT2997023T (pt) * 2013-05-17 2017-05-31 Incyte Corp Derivados de bipirazole como inibidores da jak
TWI789516B (zh) 2013-08-07 2023-01-11 美商英塞特公司 Jak1抑制劑之持續釋放劑型
LT3421468T (lt) 2013-11-13 2021-01-11 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitorių paruošimo būdai
HRP20191525T1 (hr) 2013-11-13 2019-11-29 Vertex Pharma Inhibitori replikacije virusa influence
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
DK3180315T3 (da) 2014-08-15 2020-04-06 Janssen Pharmaceuticals Inc Pyrazoler
KR20170090476A (ko) 2014-12-05 2017-08-07 어레이 바이오파마 인크. 야누스 키나제 저해제로서의 4,6-치환된-피라졸로[1,5-a]피라진
CN105777754B (zh) * 2014-12-16 2019-07-26 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物
CA2979425C (en) 2015-01-20 2020-04-14 Wuxi Fortune Pharmaceutical Co., Ltd Jak inhibitor
JP6600365B2 (ja) * 2015-04-29 2019-10-30 无▲錫▼福祈制▲薬▼有限公司 Jak阻害剤
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤を調製する方法
EP3305788B1 (en) 2015-05-29 2020-08-05 Wuxi Fortune Pharmaceutical Co., Ltd Janus kinase inhibitor
AR104918A1 (es) * 2015-06-19 2017-08-23 Lilly Co Eli Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo
CN105294699B (zh) * 2015-12-04 2019-06-11 上海勋和医药科技有限公司 巴瑞替尼的制备方法
JP6770580B2 (ja) * 2016-01-26 2020-10-14 杭州華東医薬集団生物医薬有限公司Hangzhou Huadong Medicine Group Biopharmaceutical Co., Ltd. ピロロピリミジン5員環アザ環状誘導体およびその利用
JP6505956B2 (ja) * 2016-02-24 2019-04-24 ファイザー・インク JAK阻害剤としてのピラゾロ[1,5−a]ピラジン−4−イル誘導体
KR102485731B1 (ko) 2017-01-23 2023-01-05 상하이 롱우드 바이오파마슈티칼스 컴퍼니 리미티드 Jak 효소 억제제 및 이의 제조 방법과 용도
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
BR112020002674A2 (pt) 2017-08-07 2020-07-28 Joint Stock Company Biocad compostos heterocíclicos inovadores como inibidores de cdk8/19
EP3668858A1 (en) * 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
HRP20220510T1 (hr) 2018-01-30 2022-05-27 Incyte Corporation Postupci za pripravu (1-(3-fluoro-2-(trifluorometil)izonikotinil) piperidin-4-ona)
IL276725B2 (en) 2018-02-16 2024-09-01 Incyte Corp Jak1 pathway inhibitors for the treatment of cytokine-related disorders
HUE067471T2 (hu) 2018-03-30 2024-10-28 Incyte Corp Gennyes verejtékmirigy-gyulladás kezelése jak inhibitorok alkalmazásával
US20220041588A1 (en) * 2018-09-27 2022-02-10 Fochon Pharmaceuticals, Ltd. Substituted imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
ES2979163T3 (es) 2018-10-31 2024-09-24 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN111320624B (zh) * 2018-12-14 2023-05-12 中国医药研究开发中心有限公司 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途
US12404275B2 (en) 2019-04-12 2025-09-02 Primegene (Beijing) Co., Ltd. Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN111039963B (zh) * 2019-12-31 2021-03-19 卓和药业集团有限公司 Wxfl10203614水溶性类似物及其合成方法
ES2998487T3 (en) 2020-06-02 2025-02-20 Incyte Corp Processes of preparing a jak1 inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
US11957661B2 (en) 2020-12-08 2024-04-16 Incyte Corporation JAK1 pathway inhibitors for the treatment of vitiligo
IL308216A (en) 2021-05-03 2024-01-01 Incyte Corp Jak1 pathway inhibitors for the treatment of prurigo nodularis
KR20240103022A (ko) * 2021-11-12 2024-07-03 소테르 바이오파마 피티이. 리미티드 피라졸로 융합 고리 화합물 및 이의 용도
CN119421882A (zh) * 2022-04-25 2025-02-11 伊莱利利公司 Fgfr2抑制剂化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
HUP0103386A3 (en) 1998-08-21 2002-07-29 Parker Hughes Inst St Paul Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
JP2008516973A (ja) * 2004-10-15 2008-05-22 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
SI2455382T1 (sl) 2005-12-13 2017-03-31 Incyte Holdings Corporation S heteroarilom substituirani pirolo(2,3b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janus kinaze
SI2497470T1 (sl) * 2006-11-22 2016-02-29 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaz
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP2288610B8 (en) 2008-03-11 2016-10-12 Incyte Holdings Corporation Azetidine and cyclobutane derivatives as jak inhibitors
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به

Also Published As

Publication number Publication date
SG184870A1 (en) 2012-11-29
RU2012148246A (ru) 2014-05-20
KR20130094710A (ko) 2013-08-26
PH12012502046A1 (en) 2017-07-26
AU2011240808A1 (en) 2012-11-29
TWI494314B (zh) 2015-08-01
CR20120572A (es) 2013-02-20
CA2796388A1 (en) 2011-10-20
CN102985424B (zh) 2015-03-11
EP2558468B1 (en) 2015-04-01
CN102985424A (zh) 2013-03-20
CL2012002882A1 (es) 2013-02-08
US20130131039A1 (en) 2013-05-23
UY33328A (es) 2012-10-31
JP2013523884A (ja) 2013-06-17
MX2012011941A (es) 2013-08-27
JP2015205905A (ja) 2015-11-19
ZA201208544B (en) 2015-04-29
WO2011130146A1 (en) 2011-10-20
AU2011240808B2 (en) 2015-01-22
NZ603446A (en) 2014-05-30
US8962596B2 (en) 2015-02-24
AR081075A1 (es) 2012-06-06
UA109131C2 (ru) 2015-07-27
EP2558468A1 (en) 2013-02-20
TW201134827A (en) 2011-10-16

Similar Documents

Publication Publication Date Title
CO6630187A2 (es) 5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak
UY34388A (es) "5,7-IMIDAZO[1,2-c]PIRIMIDINAS SUSTITUIDAS"
CR20170309A (es) Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas
MX2019005232A (es) Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
NI201000119A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis.
CR20110261A (es) COMPUESTOS PIRAZOLO[1,5-a]PIRIMIDINA SUSTITUIDA COMO IHNIBIDORES DE TRK CINASA
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
ECSP10010510A (es) Compuestos del inhibidor de raf y métodos de uso de los mismos
CR20110621A (es) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)1h-pirazol-1-il]octano-o heptano-nitrilo como inhbidores de jak
CR20120065A (es) COMPUESTOS DE PIRAZOLO[1,5-a]PIRIMIDINA SUSTITUIDOS COMO INHIBIDORES DE TRK-QUINASA
AR067505A1 (es) Derivados de pirimidinil-piridazinona
MX390537B (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm
CU24087B1 (es) Compuestos de carbazol
PA8793301A1 (es) Imidazoles bicíclicos fusionados
UA111933C2 (uk) Піролопіридини як інгібітори кінази
UA113156C2 (xx) Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
ECSP10010361A (es) Derivados de piridazinona
ECSP12011678A (es) Metilpirrolopirimidincarboxamidas
UY32280A (es) DERIVADOS DE 6-CICLOAMINO-3-(1H-PIRROLO[2,3-b]PIRIDIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACIÓN Y SU APLICACIÓN EN TERAPÉUTICA
CO6592046A2 (es) 5-alquinil pirimidas y su uso como inhibidores de quinasa
ECSP11011535A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus
UA110108C2 (xx) Азетидинові похідні піперидин-4-ілу як інгібітори jak1
UY31680A1 (es) "agonistas de los receptores muscarínicos, composiciones, métodos de tratamiento en que se emplean y sus procesos de preparación-176"

Legal Events

Date Code Title Description
FG Application granted